Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Uwe Liebchen

Showing results (41-50 of 66) with videos related to

Pageof 7
Sort By:
Scientific Reports|October 1, 2025
Angiopoietin-2 adsorption attempt with the cytokine adsorber cytosorb in critically ill patientsHelen Graf, Caroline Gräfe, Michael Paal, et al.
Annals of Intensive Care|May 22, 2022
Does the cytokine adsorber CytoSorb<sup>®</sup> reduce vancomycin exposure in critically ill patients with sepsis or septic shock? a prospective observational studyChristina Scharf, Ferdinand Weinelt, Ines Schroeder, et al.
Antibiotics (Basel, Switzerland)|November 27, 2024
Model-Based Dose Identification of Dalbavancin for Long-Term Suppressive Outpatient Treatment of Ventricular Assist Device InfectionsUte Chiriac, Uwe Liebchen, Otto Roman Frey, et al.
Antimicrobial Agents and Chemotherapy|May 1, 2023
Systematic Evaluation of Pharmacokinetic Models for Model-Informed Precision Dosing of Meropenem in Critically Ill Patients Undergoing Continuous Renal Replacement TherapyLea Marie Schatz, Alexander Brinkmann, Anka Röhr, et al.
Antimicrobial Agents and Chemotherapy|June 27, 2023
Cefepime Population Pharmacokinetics, Antibacterial Target Attainment, and Estimated Probability of Neurotoxicity in Critically Ill PatientsMuhammad Bilal, Michael Zoller, Uwe Fuhr, et al.
Blood Purification|November 7, 2024
Albumin and Platelet Loss during the Application of CytoSorb® in Critically Ill Patients: A post hoc Analysis of the Cyto-SOLVE TrialClara Isabell Brozat, Michael Zoller, Sandra Frank, et al.
Frontiers in Cardiovascular Medicine|August 23, 2024
Serum concentrations of levosimendan and its metabolites OR-1855 and OR-1896 in cardiac surgery patients with cardiopulmonary bypassHannah Kipka, Uwe Liebchen, Max Hübner, et al.
Antibiotics (Basel, Switzerland)|July 29, 2023
Software- and TDM-Guided Dosing of Meropenem Promises High Rates of Target Attainment in Critically Ill PatientsUte Chiriac, Daniel Richter, Otto R Frey, et al.
Clinical Laboratory|September 19, 2019
Comparative LC-MS/MS and HPLC-UV Analyses of Meropenem and Piperacillin in Critically Ill PatientsMichael Paal, Marcus Heilmann, Simone Koch, et al.
Intensive Care Medicine Experimental|May 8, 2024
Can linezolid be validly measured in endotracheal aspiration in critically ill patients? A proof-of-concept trialDiana Rebholz, Uwe Liebchen, Michael Paal, et al.
Pageof 7

Showing results (41-50 of 66) with videos related to

Sort By:
Pageof 7
Scientific Reports|October 1, 2025
Angiopoietin-2 adsorption attempt with the cytokine adsorber cytosorb in critically ill patientsHelen Graf, Caroline Gräfe, Michael Paal, et al.
Annals of Intensive Care|May 22, 2022
Does the cytokine adsorber CytoSorb<sup>®</sup> reduce vancomycin exposure in critically ill patients with sepsis or septic shock? a prospective observational studyChristina Scharf, Ferdinand Weinelt, Ines Schroeder, et al.
Antibiotics (Basel, Switzerland)|November 27, 2024
Model-Based Dose Identification of Dalbavancin for Long-Term Suppressive Outpatient Treatment of Ventricular Assist Device InfectionsUte Chiriac, Uwe Liebchen, Otto Roman Frey, et al.
Antimicrobial Agents and Chemotherapy|May 1, 2023
Systematic Evaluation of Pharmacokinetic Models for Model-Informed Precision Dosing of Meropenem in Critically Ill Patients Undergoing Continuous Renal Replacement TherapyLea Marie Schatz, Alexander Brinkmann, Anka Röhr, et al.
Antimicrobial Agents and Chemotherapy|June 27, 2023
Cefepime Population Pharmacokinetics, Antibacterial Target Attainment, and Estimated Probability of Neurotoxicity in Critically Ill PatientsMuhammad Bilal, Michael Zoller, Uwe Fuhr, et al.
Blood Purification|November 7, 2024
Albumin and Platelet Loss during the Application of CytoSorb® in Critically Ill Patients: A post hoc Analysis of the Cyto-SOLVE TrialClara Isabell Brozat, Michael Zoller, Sandra Frank, et al.
Frontiers in Cardiovascular Medicine|August 23, 2024
Serum concentrations of levosimendan and its metabolites OR-1855 and OR-1896 in cardiac surgery patients with cardiopulmonary bypassHannah Kipka, Uwe Liebchen, Max Hübner, et al.
Antibiotics (Basel, Switzerland)|July 29, 2023
Software- and TDM-Guided Dosing of Meropenem Promises High Rates of Target Attainment in Critically Ill PatientsUte Chiriac, Daniel Richter, Otto R Frey, et al.
Clinical Laboratory|September 19, 2019
Comparative LC-MS/MS and HPLC-UV Analyses of Meropenem and Piperacillin in Critically Ill PatientsMichael Paal, Marcus Heilmann, Simone Koch, et al.
Intensive Care Medicine Experimental|May 8, 2024
Can linezolid be validly measured in endotracheal aspiration in critically ill patients? A proof-of-concept trialDiana Rebholz, Uwe Liebchen, Michael Paal, et al.
Pageof 7